Skip to main content

Advertisement

SpringerLink
Log in

Central nervous system prophylaxis in patients with aggressive diffuse large B cell lymphoma: An analysis of 3,258 patients in a single center

  • Original Paper
  • Published:
Medical Oncology Aims and scope Submit manuscript

Abstract

Central nervous system (CNS) relapse continues to be a frequent and usually fatal complication in patients with diffuse large B cell lymphoma (DLBCL). Multiple factors identify the possibility of relapse and justify neurological prophylaxis; however, most of these have not been confirmed. Thus, the use of prophylaxis has not been defined. From 1988 to 2008, 3,258 patients with DLBCL with higher clinical risks and multiple extranodal involvement that have been treated with standard anthracycline-based chemotherapy: CHOP (cyclophosphamide, doxorubicin, vincristine and prednisone) or CHOP-R (CHOP plus rituximab) and that achieve complete response were retrospectively analyzed to assess the efficacy of CNS prophylaxis. One thousand five patients received different schedules for CNS prophylaxis, and 2,253 patients did not receive CNS prophylaxis. CNS relapse was similar in patients who receive prophylaxis (6 %) compared to patients who did not receive prophylaxis (5.9 %). Overall survival of patients who either receive or did not receive prophylaxis was not statistically significant: 49 % versus 53 % (p = 0.802). Thus, it seems that CNS prophylaxis did not improve outcome in this special setting of patients, and no prognostic factors to predict the presence of CNS relapse were identified. It is evident that multicentric studies are necessary to define the role of prophylaxis in order to prevent CNS relapse and that the therapeutic procedure will be carefully revised.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Siegal T, Goldschmid T. CNS prophylaxis in diffuse large B-cell lymphoma. If, when, how and for whom. Blood Rev. 2011;26:97–106.

    Article  Google Scholar 

  2. McMillan A. Central nervous system direct preventive therapy in adults with lymphoma. Br J Haematol. 2005;131:13–21.

    Article  PubMed  CAS  Google Scholar 

  3. Franklin JC, Firlay J. Leukemia and lymphomas: treatment and prophylaxis of the central nervous system. Curr Treat Options Neurol. 2006;8:335–44.

    Article  PubMed  Google Scholar 

  4. Kridel R, Dietrich PY. Prevention of CNS relapse in diffuse large B-cell lymphoma. Lancet Oncol. 2011;12:1258–66.

    Article  PubMed  Google Scholar 

  5. Hill QA, Owen RG. CNS prophylaxis in lymphoma: who to target and therapy to use. Blood Rev. 2006;20:319–32.

    Article  PubMed  Google Scholar 

  6. Cheung CW, Burton C, Smith P, Lich DC, Hoskin PJ, Ardeshna KM. Central nervous system chemoprophylaxis in non-Hodgkin’s lymphoma. Br J Haematol. 2005;131:193–200.

    Article  PubMed  CAS  Google Scholar 

  7. Bernstein SH, Unger JM, LeBlanc M, Friedberg J, Miller TP, Fisher RI. Natural history of CNS relapse in patients with aggressive non-Hodgkin’s lymphoma. J Clin Oncol. 2008;27:114–9.

    Article  PubMed  Google Scholar 

  8. Haioun C, Besson C, Lepage C, Thieblemont C, Simon D, Rose C, et al. Incidence and risk factors of central nervous system relapse in histologically aggressive non-Hodgkin’s lymphoma uniformly treated and receiving intrathecal central nervous system prophylaxis. Ann Oncol. 2000;11:685–90.

    Article  PubMed  CAS  Google Scholar 

  9. Shimazu Y, Notohara K, Veda Y. Diffuse large B-cell lymphoma with central nervous system relapse. Prognosis and risk factors according to retrospective analysis from an single-center experience. Int J Hematol. 2009;89:577–83.

    Article  PubMed  CAS  Google Scholar 

  10. Chihara D, Oki Y, Matsuo K, Onoda H, Taji H, Yamamoto K, et al. Incidence and risk-factors for central nervous system relapse in patients with diffuse large B-cell lymphoma. Leuk Lymphoma. 2011;52:2270–5.

    Article  PubMed  CAS  Google Scholar 

  11. Boehme V, Zeynalova S, Kloess M, Loefler M, Kaiser U, Pfreudschuh M, et al. Incidence and risk factors of central nervous system recurrence in aggressive lymphoma. A survey of 1,693 patients treated in protocols of the German High-grade non-Hodgkin’s Lymphoma Study Group. Ann Oncol. 2007;18:149–57.

    Article  PubMed  CAS  Google Scholar 

  12. Kim SJ, Oh SY, Kim JS, Kim H, Lee GW, Won JH, et al. Secondary central nervous system involvement in patients with diffuse large B-cell lymphoma. Ann Hematol. 2011;90:539–46.

    Article  PubMed  CAS  Google Scholar 

  13. Bollem ELEM, Brouwer RE, Hamers S, Hermans J, Kluis M, Sankatsing RVA. Central nervous system non-Hodgkin’s lymphoma. Arch Neurol. 1997;54:854–9.

    Article  Google Scholar 

  14. Boehme V, Schimtz N, Zeynalova S, Loeffler M, Pfreudschuh M. CNS events in elderly patients with aggressive lymphoma treated with modern chemotherapy (CHOP-14) with or without rituximab. Blood. 2009;113:3896–902.

    Article  PubMed  CAS  Google Scholar 

  15. Hollender A, Kualoy S, Nome E, Skovlunde-Lote K, Holte H. Central nervous system involving following diagnosis of non-Hodgkin’s lymphoma. Ann Oncol. 2002;13:1099–107.

    Article  PubMed  CAS  Google Scholar 

  16. Tilly H, Lepage E, Coiffier B, et al. Intensive conventional chemotherapy (ACVBP) regimen compared with standard CHOP for poor prognosis aggressive non-Hodgkin’s lymphoma. Blood. 2003;102:4283–9.

    Article  Google Scholar 

  17. Recher C, Coiffier B, Haioun C, et al. Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma. Lancet. 2011;378:1858–67.

    Article  PubMed  CAS  Google Scholar 

  18. Abramson JS, Hellman M, Barnes JA, Hammerman P, Toomey C, Takuvian T, et al. Intravenous methotrexate as central nervous system (CNS) prophylaxis is associated with a low-risk of CNS recurrence in high-risk patients with diffuse large B-cell lymphoma. Cancer. 2010;116:4283–90.

    Article  PubMed  Google Scholar 

  19. Mitrovic Z, Bast M, Bierman PI, Bociek RG, Vose JM, Chan WC et al. The addition of rituximab reduces the incidence of secondary central nervous system involvement in patients with diffuse large B-cell lymphoma. Br j Haematol. 2012.

  20. Feugier P, Virion JM, Tilly H, Haioun C, Marit G, Macro M, et al. Incidence and risk for central nervous system recurrence in elderly patients with diffuse large B-cell lymphoma. Influence of rituximab. Ann Oncol. 2004;15:129–33.

    Article  PubMed  CAS  Google Scholar 

  21. Tai WM, Chune J, Tang PL, Koo YY, Hou X, Tay KW, et al. Central nervous system relapse in diffuse large B-cell lymphoma (DLBCL) Pre and post-rituximab. Ann Hematol. 2011;90:809–18.

    Article  PubMed  CAS  Google Scholar 

  22. Arkenau HT, Chont G, Cunningham D, Watkins D, Agarwai R, Sirohi B, et al. The role of intrathecal chemotherapy prophylaxis in patients with diffuse large B-cell lymphoma. Ann Oncol. 2007;18:541–8.

    Article  PubMed  Google Scholar 

  23. Avilés A, Castañeda C, Neri N, Cleto S, Nambo MJ. Rituximab and dose-dense therapy in primary breast lymphoma. Haematologica. 2007;92:1147–8.

    Article  PubMed  Google Scholar 

  24. Avilés A, Neri N, Huerta-Guzmán J, et al. Testicular lymphoma. Organ-specific treatment did not improve outcome. Oncology. 2004;67:211–4.

    Article  PubMed  Google Scholar 

  25. Avilés A, Fernández R, Pérez F, et al. Adjuvant radiotherapy in stage IV diffuse large B-cell lymphoma improve outcome. Leuk Lymphoma. 2004;45:385–9.

    Google Scholar 

  26. Hedge UL, Filie A, Little RF, Janik JE, Grant JN, Steinbergs M, et al. High-incidence of occult leptomeningeal disease detected by flow cytometry in newly diagnosed aggressive B-cell lymphomas at risk for central nervous system involvement. Blood. 2005;105:496–502.

    Article  Google Scholar 

  27. Ahluwalid MS, Wallace PB, Peereboom DM. Flow-cytometry as a diagnostic tool in lymphomatous or leukemia meningitis. Cancer. 2012;118:1747–53.

    Article  Google Scholar 

  28. Tanimoto T, Kusumi E, Hosuda K, et al. CNC prophylaxis in diffuse large B-cell lymphoma. Lancet. 2012;379:1485–6. (Letter).

    Article  PubMed  Google Scholar 

  29. Jabbour E, O’Brien S, Garcia-Manero G, Fernadoli A, Ravandi F, Cabanillas M, et al. Neurologic complications associated with intrathecal liposomal cytarabine given prophylactically in combination with high-dose methotrexate and cytarabine to patients with acute leucemia. Blood. 2007;109:3214–8.

    Article  PubMed  CAS  Google Scholar 

  30. Perez-Larray JG, Palma JA, Carmona-Iragus M, Fernández-Torron R, Irimiz P, Rodríguez-Otero P, et al. Neurologic complications of intrathecal liposomal cytarabine administered prophylactically to patients with non-Hodgkin’s lymphoma. J Neurooncol. 2011;103:603–9.

    Article  Google Scholar 

Download references

Acknowledgments

The study was performed with the owner resources of the Mexican Institute of Social Security and did not receive any financial support.

Conflict of interest

The authors disclose no conflict of interest.

Author information

Authors and Affiliations

  1. Oncology Research Oncology Diseases, Ave. Cuauhtemoc 330, Colonia Doctores, 06725, Mexico, D.F., Mexico

    Agustin Avilés

  2. Department of Hematology, Oncology Hospital, National Medical Center, IMSS, Mexico, D.F., Mexico

    M. Jesús Nambo & Natividad Neri

Authors
  1. Agustin Avilés
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M. Jesús Nambo
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Natividad Neri
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Agustin Avilés.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Avilés, A., Jesús Nambo, M. & Neri, N. Central nervous system prophylaxis in patients with aggressive diffuse large B cell lymphoma: An analysis of 3,258 patients in a single center. Med Oncol 30, 520 (2013). https://doi.org/10.1007/s12032-013-0520-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s12032-013-0520-0

Keywords

Search

Navigation